From Fat Selectivity to Rebound Prevention: Translating RES-010 from Target Discovery to Clinical Development
11:45 am - Thursday 29th October 2026
- Exploring miR-22 inhibition as a novel therapeutic approach to increase energy expenditure without appetite suppression
- Demonstrating the differentiated profile of RES-010 through preclinical studies showing weight loss with preservation of muscle and bone health, together with benefits across multiple obesity-related comorbidities.
- Translating preclinical discoveries into clinical development, highlighting Phase I/IB progress and non-human primate combination studies with semaglutide that support RES-010 as a differentiated, orthogonal approach for the treatment of obesity and its complications.
